iM4TB awarded USD 769’000 for anti-TB drug formulation development

Posted on by in PBTZ169 | Leave a comment

EPFL-based non-profit iM4TB has received a two-year grant of USD 769’000 from the Bill & Melinda Gates Foundation to improve the formulation of their innovative anti-tuberculosis drug PBTZ169.

Comments are closed.